321 related articles for article (PubMed ID: 33484750)
1. Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells.
Russkamp NF; Myburgh R; Kiefer JD; Neri D; Manz MG
Exp Hematol; 2021 Mar; 95():31-45. PubMed ID: 33484750
[TBL] [Abstract][Full Text] [Related]
2. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.
Myburgh R; Kiefer JD; Russkamp NF; Magnani CF; Nuñez N; Simonis A; Pfister S; Wilk CM; McHugh D; Friemel J; Müller AM; Becher B; Münz C; van den Broek M; Neri D; Manz MG
Leukemia; 2020 Oct; 34(10):2688-2703. PubMed ID: 32358567
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.
Pang WW; Czechowicz A; Logan AC; Bhardwaj R; Poyser J; Park CY; Weissman IL; Shizuru JA
Blood; 2019 May; 133(19):2069-2078. PubMed ID: 30745302
[TBL] [Abstract][Full Text] [Related]
4. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation.
Czechowicz A; Palchaudhuri R; Scheck A; Hu Y; Hoggatt J; Saez B; Pang WW; Mansour MK; Tate TA; Chan YY; Walck E; Wernig G; Shizuru JA; Winau F; Scadden DT; Rossi DJ
Nat Commun; 2019 Feb; 10(1):617. PubMed ID: 30728354
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
6. Non-genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia.
Chan YY; Ho PY; Swartzrock L; Rayburn M; Nofal R; Thongthip S; Weinberg KI; Czechowicz A
Transplant Cell Ther; 2023 Mar; 29(3):164.e1-164.e9. PubMed ID: 35995393
[TBL] [Abstract][Full Text] [Related]
7. Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment.
Arai Y; Choi U; Corsino CI; Koontz SM; Tajima M; Sweeney CL; Black MA; Feldman SA; Dinauer MC; Malech HL
Mol Ther; 2018 May; 26(5):1181-1197. PubMed ID: 29622475
[TBL] [Abstract][Full Text] [Related]
8. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
Ragon BK
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
[TBL] [Abstract][Full Text] [Related]
9. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy.
Chhabra A; Ring AM; Weiskopf K; Schnorr PJ; Gordon S; Le AC; Kwon HS; Ring NG; Volkmer J; Ho PY; Tseng S; Weissman IL; Shizuru JA
Sci Transl Med; 2016 Aug; 8(351):351ra105. PubMed ID: 27510901
[TBL] [Abstract][Full Text] [Related]
13. Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Schneider S; Strumpf A; Schetelig J; Wunderlich G; Ehninger G; Kotzerke J; Bornhäuser M
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1754-60. PubMed ID: 26001695
[TBL] [Abstract][Full Text] [Related]
14. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
15. Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice.
Xue X; Pech NK; Shelley WC; Srour EF; Yoder MC; Dinauer MC
Blood; 2010 Dec; 116(24):5419-22. PubMed ID: 20813896
[TBL] [Abstract][Full Text] [Related]
16. In vivo hematopoietic stem cell modification by mRNA delivery.
Breda L; Papp TE; Triebwasser MP; Yadegari A; Fedorky MT; Tanaka N; Abdulmalik O; Pavani G; Wang Y; Grupp SA; Chou ST; Ni H; Mui BL; Tam YK; Weissman D; Rivella S; Parhiz H
Science; 2023 Jul; 381(6656):436-443. PubMed ID: 37499029
[TBL] [Abstract][Full Text] [Related]
17. Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment.
Coorens THH; Collord G; Lu W; Mitchell E; Ijaz J; Roberts T; Oliver TRW; Burke GAA; Gattens M; Dickens E; Nangalia J; Tischkowitz M; Anderson J; Shlien A; Godfrey AL; Murray MJ; Behjati S
Blood; 2021 May; 137(21):2992-2997. PubMed ID: 33598691
[No Abstract] [Full Text] [Related]
18. Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.
Slavin S; Morecki S; Weiss L; Or R
Crit Rev Oncol Hematol; 2003 May; 46(2):139-63. PubMed ID: 12711359
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant.
Yeung J; Liao A; Shaw M; Silva S; Vetharoy W; Rico DL; Kirby I; Zammarchi F; Havenith K; de Haan L; van Berkel PH; Sebire N; Ogunbiyi OK; Booth C; Gaspar HB; Thrasher AJ; Chester KA; Amrolia PJ
Mol Ther; 2024 Jun; 32(6):1672-1686. PubMed ID: 38549377
[TBL] [Abstract][Full Text] [Related]
20. Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.
Advani AS
Curr Hematol Malig Rep; 2006 Jun; 1(2):101-7. PubMed ID: 20425339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
